Advanced Clinical Flow Cytometry Solutions for Oncology Research
Unlocking Cellular Insights with Precision and Expertise
Flow cytometry is becoming a critical tool in clinical trials, especially in immuno-oncology. Cell therapy such as CAR-T and CAR-NK often utilize flow cytometry to monitor the persistence and differentiation of the cells during treatment. Multi-color flow cytometry assays allow for the identification and quantification of different cell types in a single heterogeneous sample and provide information about the frequency, phenotypes, or drug binding of specific cell populations. Flow cytometry assays are a valuable endpoint in clinical trials to help assess a drug or cell therapy’s effect. Whole blood, PBMC, or bone marrow aspirate may be used as samples. We have extensive expertise in these areas:
- Immunophenotyping
- Receptor Occupancy Assays (ROA)
- Biomarker Assay Development
- Evaluation of Cell Surface and Intra-Cellular Markers
- Qualification/Validation of Flow Cytometry Assays
- Manufacturing Release Assays for Cell Therapies
- GLP Flow Cytometry
While it is not a requirement for every clinical flow cytometry assay, we are able to perform work in compliance with Good Laboratory Practice (GLP).
For example, standard TBNK panels are gated through CD45+ Lymphocytes to CD3+ cells, and then to CD4 (T Helper) and CD8 (T Effector) populations. B cells are identified as CD3-CD20+ and NK cells as CD3-CD16+. Examples of Non-Human Primate Panel A and Human Panel B TBNK results are shown below.
Request more information about our Clinical Flow Cytometry Services
Contact our experts to help advance your drug development with TD2's Comprehensive Oncology Ecosystem.
Additional Resources
Comprehensive
Clinical Trial Services Include:
GET STARTED
Work with a team who believes in your research as much as you do.
Are you ready to accelerate your drug development? Partner with a collaborative oncology CRO that believes in your treatment as much as you do. Take the first step today and contact our experts.